Cetuximab is a monoclonal antibody that targets EGFR, which can specifically bind to the extracellular EGFR domains expressed on the surface of a variety of cancer cells and competitively block the combination between EGFR and corresponding ligands [31]. The gene discussed is EGFR; the disease is cancer.